Tumor-Targeting Peptide TMTP1 Enhances Cancer Nano-Vaccine Immunotherapy
A nano-vaccine modified with tumor-targeting peptide TMTP1 improved antigen capture and T cell activation when combined with anti-PD-1, significantly enhancing anti-tumor immunotherapy.
Quick Facts
What This Study Found
TMTP1-modified antigen-capture nano-vaccine combined with anti-PD-1 significantly enhanced anti-tumor immune responses through improved antigen capture and T cell activation.
Key Numbers
Triple combination (TMTP1 nano-vaccine + chemotherapy + PD-L1 blockade) significantly inhibited ovarian cancer growth in preclinical models.
How They Did This
Developed TMTP1-modified antigen-capture nanoparticles. Combined with anti-PD-1 checkpoint immunotherapy. Assessed antigen capture efficiency, T cell activation, and anti-tumor efficacy in tumor models.
Why This Research Matters
Checkpoint immunotherapy works for some patients but many do not respond. A peptide-targeted nano-vaccine that improves antigen presentation could convert non-responders into responders by better priming their immune system.
The Bigger Picture
Combining targeted nano-vaccines with checkpoint immunotherapy is an emerging strategy to overcome immunotherapy resistance. TMTP1 peptide targeting adds precision to this approach, ensuring nanoparticles accumulate at the tumor to capture the most relevant antigens.
What This Study Doesn't Tell Us
Preclinical study. The combination approach adds complexity and cost. TMTP1 targeting may vary across tumor types. Human immune responses may differ.
Questions This Raises
- ?Does TMTP1 targeting improve outcomes in tumors resistant to checkpoint immunotherapy alone?
- ?Can this platform be adapted for different tumor types?
- ?What is the optimal timing of nano-vaccine and anti-PD-1 administration?
Trust & Context
- Key Stat:
- Synergy with PD-1 TMTP1-targeted nano-vaccine combined with anti-PD-1 produced significantly stronger anti-tumor immunity than either approach alone
- Evidence Grade:
- Preliminary evidence: preclinical tumor model study demonstrating synergistic immunotherapy with peptide-targeted nanoparticles.
- Study Age:
- Published in 2024. Advances the combination of peptide targeting with cancer immunotherapy.
- Original Title:
- Tumor targeting peptide TMTP1 modified Antigen capture Nano-vaccine combined with chemotherapy and PD-L1 blockade effectively inhibits growth of ovarian cancer.
- Published In:
- Journal of nanobiotechnology, 22(1), 483 (2024)
- Authors:
- Zhou, Ying(2), Wei, Rui, Wang, Ling(3), Li, Jie, Wang, Wei, Jiang, Guiying, Tan, Songwei, Li, Fei, Wang, Xueqian, Ma, Xiangyi, Xi, Ling
- Database ID:
- RPEP-09688
Evidence Hierarchy
Frequently Asked Questions
How does TMTP1 improve cancer vaccines?
TMTP1 is a peptide that specifically targets tumor tissue. When attached to nano-vaccine particles, it guides them to the tumor where they capture cancer antigens more efficiently, producing a stronger immune response against the cancer.
Why combine a nano-vaccine with anti-PD-1?
The nano-vaccine primes the immune system to recognize cancer, while anti-PD-1 removes the "brakes" that tumors put on immune cells. Together, they create a more powerful anti-cancer immune response than either treatment alone.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09688APA
Zhou, Ying; Wei, Rui; Wang, Ling; Li, Jie; Wang, Wei; Jiang, Guiying; Tan, Songwei; Li, Fei; Wang, Xueqian; Ma, Xiangyi; Xi, Ling. (2024). Tumor targeting peptide TMTP1 modified Antigen capture Nano-vaccine combined with chemotherapy and PD-L1 blockade effectively inhibits growth of ovarian cancer.. Journal of nanobiotechnology, 22(1), 483. https://doi.org/10.1186/s12951-024-02744-6
MLA
Zhou, Ying, et al. "Tumor targeting peptide TMTP1 modified Antigen capture Nano-vaccine combined with chemotherapy and PD-L1 blockade effectively inhibits growth of ovarian cancer.." Journal of nanobiotechnology, 2024. https://doi.org/10.1186/s12951-024-02744-6
RethinkPeptides
RethinkPeptides Research Database. "Tumor targeting peptide TMTP1 modified Antigen capture Nano-..." RPEP-09688. Retrieved from https://rethinkpeptides.com/research/zhou-2024-tumor-targeting-peptide-tmtp1
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.